🚀 VC round data is live in beta, check it out!
Cartesian Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cartesian Therapeutics and similar public comparables like Tonix Pharmaceuticals, BioVersys, EQL Pharma, Scancell and more.
Cartesian Therapeutics Overview
About Cartesian Therapeutics
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Founded
2007
HQ
Employees
66
Website
Sectors
Financials (LTM)
EV
$48M
Cartesian Therapeutics Financials
Cartesian Therapeutics reported last 12-month revenue of $2M.
In the same LTM period, Cartesian Therapeutics generated $2M in gross profit and had net loss of ($124M).
Revenue (LTM)
Cartesian Therapeutics P&L
In the most recent fiscal year, Cartesian Therapeutics reported revenue of $39M and EBITDA of ($76M).
Cartesian Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $39M | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($76M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (195%) | XXX | XXX | XXX |
| EBIT Margin | (5745%) | XXX | (93%) | XXX | XXX | XXX |
| Net Profit | ($124M) | XXX | ($77M) | XXX | XXX | XXX |
| Net Margin | (5275%) | XXX | (199%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cartesian Therapeutics Stock Performance
Cartesian Therapeutics has current market cap of $179M, and enterprise value of $48M.
Market Cap Evolution
Cartesian Therapeutics' stock price is $6.89.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $48M | $179M | 0.0% | XXX | XXX | XXX | $-2.98 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCartesian Therapeutics Valuation Multiples
Cartesian Therapeutics trades at 20.6x EV/Revenue multiple, and (0.6x) EV/EBITDA.
EV / Revenue (LTM)
Cartesian Therapeutics Financial Valuation Multiples
As of March 20, 2026, Cartesian Therapeutics has market cap of $179M and EV of $48M.
Equity research analysts estimate Cartesian Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cartesian Therapeutics has a P/E ratio of (1.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $179M | XXX | $179M | XXX | XXX | XXX |
| EV (current) | $48M | XXX | $48M | XXX | XXX | XXX |
| EV/Revenue | 20.6x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.6x) | XXX | XXX | XXX |
| EV/EBIT | (0.4x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 20.6x | XXX | — | XXX | XXX | XXX |
| P/E | (1.4x) | XXX | (2.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cartesian Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cartesian Therapeutics Margins & Growth Rates
Cartesian Therapeutics' revenue in the last 12 month declined by (70%).
Cartesian Therapeutics' revenue per employee in the last FY averaged $0.0M.
Cartesian Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (70%) | XXX | (93%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (195%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (68%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1383% | XXX | 77% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2879% | XXX | 116% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 193% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cartesian Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tonix Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| BioVersys | XXX | XXX | XXX | XXX | XXX | XXX |
| EQL Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Scancell | XXX | XXX | XXX | XXX | XXX | XXX |
| PhotoCure | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cartesian Therapeutics M&A Activity
Cartesian Therapeutics acquired XXX companies to date.
Last acquisition by Cartesian Therapeutics was on XXXXXXXX, XXXXX. Cartesian Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cartesian Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCartesian Therapeutics Investment Activity
Cartesian Therapeutics invested in XXX companies to date.
Cartesian Therapeutics made its latest investment on XXXXXXXX, XXXXX. Cartesian Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cartesian Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cartesian Therapeutics
| When was Cartesian Therapeutics founded? | Cartesian Therapeutics was founded in 2007. |
| Where is Cartesian Therapeutics headquartered? | Cartesian Therapeutics is headquartered in United States. |
| How many employees does Cartesian Therapeutics have? | As of today, Cartesian Therapeutics has over 66 employees. |
| Who is the CEO of Cartesian Therapeutics? | Cartesian Therapeutics' CEO is Carsten Brunn. |
| Is Cartesian Therapeutics publicly listed? | Yes, Cartesian Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Cartesian Therapeutics? | Cartesian Therapeutics trades under RNAC ticker. |
| When did Cartesian Therapeutics go public? | Cartesian Therapeutics went public in 2016. |
| Who are competitors of Cartesian Therapeutics? | Cartesian Therapeutics main competitors are Tonix Pharmaceuticals, BioVersys, EQL Pharma, Scancell. |
| What is the current market cap of Cartesian Therapeutics? | Cartesian Therapeutics' current market cap is $179M. |
| What is the current revenue of Cartesian Therapeutics? | Cartesian Therapeutics' last 12 months revenue is $2M. |
| What is the current revenue growth of Cartesian Therapeutics? | Cartesian Therapeutics revenue growth (NTM/LTM) is (70%). |
| What is the current EV/Revenue multiple of Cartesian Therapeutics? | Current revenue multiple of Cartesian Therapeutics is 20.6x. |
| Is Cartesian Therapeutics profitable? | No, Cartesian Therapeutics is not profitable. |
| What is the current net income of Cartesian Therapeutics? | Cartesian Therapeutics' last 12 months net income is ($124M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.